Trend Innovations names new CEO Kenneth Waggoner; ex-CEO Tunevic stays as President

AVAI BIO, INC.

Kenneth L. Waggoner named CEO on Apr 20, 2023, replacing Natalija Tunevic who remains President and director.
Annual base salary of $720,000 in common stock, retroactively increased to $1,440,000 upon listing on a national exchange.
Shares paid quarterly: $180,000 per quarter divided by 20-day VWAP; $2,500/mo health plan also paid in shares.
Agreement term one year from April 20, 2023, auto-renewing; includes confidentiality, invention assignment, and indemnification.
Waggoner has 45 years experience, including as CEO of PharmaCyte Biotech (2013-2022) and partner at Brobeck.

item 1.01 item 3.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Natalija Tunevic

President

AVAI · AVAI BIO, INC.

Effective: 2023-04-20
Successor: Kenneth L. Waggoner
Filed: April 24, 2023, 7:59 PM ET

Natalija Tunevic resigned as CEO of the Company but will continue to serve as President and a director of the Company.

Appointed

Kenneth L. Waggoner

Chief Executive Officer

AVAI · AVAI BIO, INC.

Effective: 2023-04-20
Filed: April 24, 2023, 7:59 PM ET

On April 20, 2023, Trend Innovations Holding Inc. (the “Company”) and Kenneth L. Waggoner entered into an Executive Compensation Agreement pursuant to which Mr. Waggoner was retained as Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Natalija Tunevic departed as President at AVAI BIO, INC..

Action: resigned as CEO
Role: President

Exact text from the filing

Natalija Tunevic resigned as CEO of the Company but will continue to serve as President and a director of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Kenneth L. Waggoner was appointed as Chief Executive Officer at AVAI BIO, INC..

Action: retained
Role: Chief Executive Officer

Exact text from the filing

On April 20, 2023, Trend Innovations Holding Inc. (the “Company”) and Kenneth L. Waggoner entered into an Executive Compensation Agreement pursuant to which Mr. Waggoner was retained as Chief Executive Officer.

View on SEC.gov

AVAI BIO, INC. filing history →

Source: SEC EDGAR

accession 0001740797-23-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.